NTRC launches new website: www.residencetimer.com

July 30th, 2020|

July 30, 2020: NTRC launches www.residencetimer.com for biochemical assays in drug discovery. Biochemical assays for determination of binding characteristics Oss, July, 30, 2020 – NTRC Precision Medicine Services proudly [...]

  • logo AACR 2020 virtual meeting. NTRC presents a poster on High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites

NTRC Presents at AACR Virtual Annual Meeting II

June 23rd, 2020|

June 23, 2020: NTRC presents the poster #5604, titled 'High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites' at the AACR Virtual Annual Meeting II. High [...]

NTRC presents at Rare Diseases and Orphan Drugs conference

October 28th, 2018|

Oss, October, 28th, 2018 – At the Rare Diseases and Orphan Drugs Global Forum, held in Belgrade (Serbia) 1st and 2nd November, Dr. Guido Zaman will present on NTRC’s precision medicine platforms for drug discovery [...]

Oncolines™ at Discovery on Target conference in Boston

September 26th, 2018|

Oss, September 25th, 2018 – In the Kinase Inhibitor symposium of the Discovery on Target conference, held in Boston this week, Dr. Guido Zaman will present the Oncolines™ profiling of all kinase inhibitors that have [...]

NTRC expands ResidenceTimer™ platform with BTK resistance mutants

April 5th, 2018|

Oss, April, 5th, 2018 –NTRC’s ResidenceTimer™ platform enables the determination of the binding kinetics of small molecule kinase inhibitors to their target enzymes. Advantages include: (i) the accurate determination of compound affinity and selectivity; and [...]

NTRC’s key TTK kinase inhibitor patent granted in US

September 25th, 2017|

Oss, September, 19th , 2017 – NTRC, a biopharmaceutical company focused on the discovery and development of innovative precision medicines for the treatment of cancer, today announced that the United States Patent and Trademarks Office [...]

NTRC expands Oncolines™ cell line panel to 102 cell lines

June 23rd, 2017|

Oss, June 22nd 2017 – Today NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines. Oncolines™ are proliferation assays on a panel of genetically well-characterized cancer [...]

Structural insight into the function of TDO in healthy aging

December 23rd, 2016|

Oss, Groningen, December, 23rd, 2016 – Researchers from the European Research Institute for the Biology of Aging (ERIBA) University of Groningen, the Netherlands) in collaboration with the Netherlands Translational Research Center B.V. have identified an [...]

NTRC to join EU mission to Japan and to present at BIO Japan

September 18th, 2016|

Oss, September, 13th, 2016 – NTRC will join a mission of European biotechnology companies to Japan, which has been organized by the EU-Japan Centre for Industrial Cooperation. Twenty representatives from eight different European countries, mainly [...]

NTRC launches comparative cancer cell line profiling

September 14th, 2015|

Oss, September, 14th, 2015 – NTRC today announced that it has extended its bioinformatics analysis to its Oncolines™ cancer cell line profiling service. OncolinesProfiler™ involves the comparison of a clients’ compound against more than 100 [...]

Whole genome doubling causes multidrug resistance

July 8th, 2015|

Oss, July 7th, 2015 – In a new study in Cell Cycle, researchers from the Max Planck Institute and NTRC show that doubling of the whole genome of human cancer cells provides resistance to a [...]

SynergyFinder™ presented at AACR 2015 in Philadelphia

April 7th, 2015|

Guido Zaman, Suzanne van Gerwen, Joost Uitdehaag and Jos de Man will attend the Annual Meeting 2015 of the American Association for Cancer Research (AACR), that we be held in Philadelphia (U.S.A.) from April 18th [...]

NTRC launches assay for mouse IDO1 and mouse TDO activity

January 15th, 2015|

Cancer immunotherapy aims at the stimulation of the body’s immune system to fight cancer. The T-cell immune response against cancer cells is dampened by the activity of the enzymes indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase [...]

NFK GreenScreen™ presented at CHAINS conference in Veldhoven

November 12th, 2014|

Nicole Willemsen-Seegers and Joost Uitdehaag will attend the NWO Chemical Sciences conference CHAINS 2014, that will be held in Veldhoven (The Netherlands) on November 17th and 18th. On Monday, November 17th, Joost Uitdehaag will give [...]

NTRC launches Oncolines™ 66 cell line panel

October 1st, 2014|

NTRC has extended its Oncolines™ cancer cell line panel to 66 cancer cell lines. The Oncolines™ panel represents a broad range of tumor tissues and all most frequent genetic changes in human cancer. The previous [...]

Reverse Phase Protein Array workshop in Paris sponsored by NTRC

August 25th, 2014|

The 4th Global Reverse Phase Protein Array Workshop will take place on October 24-25 at Cité Internationale Universitaire in Paris. The workshop brings together RPPA laboratories, vendors and users to share and discuss results, latest [...]

NTRC will attend BIO 2014 in San Diego

May 5th, 2014|

Gavin Clark, VP Business Development of NTRC, will attend BIO 2014 Conference held in San Diego from June 21st to June 26th. Gavin Clark will be available to meet with interested parties from pharmaceutical industries [...]

NTRC will present at BioEurope 2013

October 13th, 2013|

NTRC will present at BioEurope 2013 in Vienna. Date: November 4th-6th, 2013 Time: 9:40 Session: Next Generation www.ebdgroup.com/bioeurope/

Oncolines™ presented at the European Cancer Congress 2013

September 26th, 2013|

Joost Uitdehaag will present during the European Cancer Congress 2013. The poster entitled 'Drug sensitivity markers for approved kinase inhibitor drugs from cell panel profiling' decribes the recent results obtained after profiling and bioinformatic analysis [...]

NTRC starts at the Life Sciences Park Oss

June 6th, 2012|

Oss – 6 June 2012 - Netherlands Translational Research Center B.V. (NTRC) starts operations at the Life Sciences Park Oss, after successful closing its first round of financing. With the financial support of the Brabant [...]